The pharmaceutical company Biogen has today announced the results of an extended phase 1b clinical trial of the potential Alzheimer’s disease drug, aducanumab. Results from the extended early stage trial, were announced today at Clinical Trials in Alzheimer’s Disease (CTAD) conference in Boston.
from Dementia Big http://ift.tt/2gZuD7G via alcoholic dementia
http://ift.tt/2zctwMO
No comments:
Post a Comment